All of the leading coronavirus vaccine candidates share one quality: They seek to spur the body's immune system to fight future infections of the virus that causes COVID-19. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Keith Speights discuss the main differences between the leading coronavirus vaccines in development. Corinne Cardina: So let's get into the stocks.
The news shows progress is being made in measures to combat the coronavirus. Positive vaccine news usually leads to optimism in the stock market as investors look to a return to relative normality.
"In addition to the manufacturing costs, the company is incurring costs in excess of $1 billion globally that include clinical development, regulatory, distribution, pharmacovigilance and other expenses", an AstraZeneca spokesman said in a statement. "To cover these additional expenses, the company will add an amount equivalent to a maximum of 20% of the manufacturing costs to ensure there is no material impact on its finances this year while continuing efforts to provide the vaccine at no profit during the pandemic," the statement added.